StockData
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. (WHWK) stock

WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.13+0.05 (+1.62%)

Close on Nov 18, 2026Market cap $178.44MP/E –Yield –

Whitehawk Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Whitehawk Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$86.06M. For fiscal 2025 it was -$114.40M. The highest annual figure on record is -$20.51K in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$114.40M–
FY2024Dec 31, 2024-$67.46M–
FY2023Dec 31, 2023-$71.93M–
FY2022Dec 31, 2022-$62.68M–
FY2021Dec 31, 2021-$111.22M–
FY2020Dec 31, 2020-$2.55M–
FY2019Dec 31, 2019-$24.44M–
FY2018Dec 31, 2018-$11.18M–
FY2017Dec 31, 2017-$21.39M–
FY2016Dec 31, 2016-$16.63M–
FY2015Dec 31, 2015-$23.01K–
FY2014Dec 31, 2014-$23.97K–
FY2013Dec 31, 2013-$22.82K–
FY2012Dec 31, 2012-$22.39K–
FY2011Dec 31, 2011-$23.59K–
FY2010Dec 31, 2010-$20.51K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$18.11M–
Q1 FY2026Mar 31, 2026-$23.52M–
Q4 FY2025Dec 31, 2025-$24.89M–
Q3 FY2025Sep 30, 2025-$19.55M–
Q2 FY2025Jun 30, 2025-$54.75M–
Q1 FY2025Mar 31, 2025-$15.22M–
Q4 FY2024Dec 31, 2024-$18.95M–
Q3 FY2024Sep 30, 2024-$13.41M–
Q2 FY2024Jun 30, 2024-$15.58M–
Q1 FY2024Mar 31, 2024-$19.51M–
Q4 FY2023Dec 31, 2023-$17.71M–
Q3 FY2023Sep 30, 2023-$17.85M–
Q2 FY2023Jun 30, 2023-$19.55M–
Q1 FY2023Mar 31, 2023-$16.83M–
Q4 FY2022Dec 31, 2022-$15.47M–
Q3 FY2022Sep 30, 2022-$15.04M–
Q2 FY2022Jun 30, 2022-$18.36M–
Q1 FY2022Mar 31, 2022-$13.81M–
Q4 FY2021Dec 31, 2021-$15.95M-289.7%
Q3 FY2021Sep 30, 2021-$87.31M–
Q2 FY2021Jun 30, 2021-$3.88M-141.9%
Q1 FY2021Mar 31, 2021-$4.09M–
Q4 FY2020Dec 31, 2020$8.40M–
Q3 FY2020Sep 30, 2020-$2.66M–
Q2 FY2020Jun 30, 2020$9.26M–
Q1 FY2020Mar 31, 2020-$4.11M–
Q4 FY2019Dec 31, 2019-$4.66M–
Q3 FY2019Sep 30, 2019-$4.97M-144.4%
Q2 FY2019Jun 30, 2019-$5.98M–
Q1 FY2019Mar 31, 2019-$8.84M–
Q4 FY2018Dec 31, 2018-$8.87M–
Q3 FY2018Sep 30, 2018$11.20M–
Q2 FY2018Jun 30, 2018-$6.04M–
Q1 FY2018Mar 31, 2018-$7.48M–
Q4 FY2017Dec 31, 2017-$6.29M–
Q3 FY2017Sep 30, 2017-$4.76M–
Q2 FY2017Jun 30, 2017-$5.58M–
Q1 FY2017Mar 31, 2017-$4.76M–
Q4 FY2016Dec 31, 2016-$3.31M–
Q3 FY2016Sep 30, 2016-$4.75M–

More Whitehawk Therapeutics figures

See a number that looks wrong?